Page last updated: 2024-09-04

irofulven and docetaxel anhydrous

irofulven has been researched along with docetaxel anhydrous in 2 studies

Compound Research Comparison

Studies (irofulven)	Trials (irofulven)	Recent Studies (post-2010) (irofulven)	Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)
99	22	7	12,110	3,216	6,920

Protein Interaction Comparison

Protein	Taxonomy	irofulven (IC50)	docetaxel anhydrous (IC50)
Kinesin-like protein KIF11	Homo sapiens (human)		0.0014
Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)		5.0119

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S	1
Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R	1

Other Studies

2 other study(ies) available for irofulven and docetaxel anhydrous

Article	Year
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. The Prostate, 2004, Apr-01, Volume: 59, Issue:1 Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Mitoxantrone; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Xenograft Model Antitumor Assays	2004
The postchemotherapy PSA surge syndrome. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome	2008

Article

Year

Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.

The Prostate, 2004, Apr-01, Volume: 59, Issue:1

Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Mitoxantrone; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Xenograft Model Antitumor Assays

2004

The postchemotherapy PSA surge syndrome.

Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome

2008